search
EmCell
THE WORLDS LARGEST CLINICAL EXPERIENCE IN EMBRYONIC STEM CELL TRANSPLANTATION FOR
VARIOUS DISEASES AND CONDITIONS.

Home
About EmCell
IMPORTANT MESSAGE
EmCell Therapy
Our Experience
List of diseases
Oncology
Diabetes Mellitus
Nervous system
Aging Problems
Immune Deficiency
Endoscopic Treatment of Liver Diseases
News
Experience of Application of Embryonic Stem Cells in Amyotrophic Lateral Sclerosis
Embryonic Stem Cells in New-Onset Type 2 Diabetes Mellitus
Embryonic Stem Cells in Pernicious Decompensated Type 2 Diabetes Mellitus
Embryonic Stem Cell Transplantation in Multiple Sclerosis
Embryonic Cell Suspensions in Rheumatoid Arthritis
Investment Projects
Clinical Trials
Publications
Patents
Mail center
Congresses and Conferences

16 YEARS OF INTERNATIONAL CLINICAL EXPERIENCE IN TRANSPLANTATION OF HUMAN EMBRYONIC/FETAL STEM CELLS. REVIEW.

Embryonic Cell Suspensions in Rheumatoid Arthritis

Embryonic Cell Suspensions in Rheumatoid Arthritis

Smikodub A.I., Demchyuk M.P.

A group of patients with Rheumatoid Arthritis (RA) has been under observation since 1995.   38 patients (32 women and 6 men) with confirmed (in accordance with diagnostic criteria) Rheumatoid Arthritis were treated with embryonic cell suspensions.  Duration of RA varied from 3 to 15 years.  In the mean, before the treatment, all the patients were reported to have III stage of RA, with stages II-III functional joint deficiency, R? – stages II-IV.   Indications for the treatment were as follows: ineffectiveness of routine methods, considerably limited range of motions in joints with marked decrease of functional capabilities, trophic disturbances of muscular and skeletal systems. 

Administered were embryonic cell suspensions containing hematopoietic and non-hematopoietic mesenchymal stem cells obtained, by cell sorting, from liver, spleen and bone marrow of 4-8 weeks old embryonic cadavers, cell count starting from 0,1x108/ml, CD34 count – 1-20x106/ml.

Before embryonic stem cell transplantation (ESCT), activity of pathological process corresponded to stage III.  After the treatment, observed was gradual decrease of activity: after 15-30 days – stage II (12 and 10 points respectively), in 3 months – stage I (6 points); after 12 months of observation, pathological activity remained minimal and corresponded to 3 points on the general scale. 

In patients with serologically negative RA (9 cases), it was possible to achieve complete remission without application of any medicinal agents.  In patients, with serologically positive RA, within a month after the treatment, RF value decreased by 65,6%, and RA remained serologically negative for all the 12 months of observation. 

Long-term observation allowed for educing of ESCT effect on RA course: the disease becomes less aggressive, pathological process – less active; clinically, reported are increase of functional capabilities, improved quality of life; no evidence of progression is shown on X-rays. 


Copyright © 1999-2008 EmCell.com     Create a WebsiteDeveloped by XTLabs, Inc.